Our Latest Articles

Contact Us

RNA Proudly Welcomes Jeff Williamson

Jeff Williamson has joined the RNA Advisors growing healthcare practice as Director.  Mr. Williamson will focus on providing a greater breadth and depth of strategic advisory services to our healthcare, medical device, and life sciences clients. Mr. Williamson brings over 15 years of strategy consulting experience in healthcare and life sciences, with particular expertise in

Read More
Commercial Operations

Client Success: Strategic Extension for Revenue-Stage Medtech

THE PROBLEM: A medical device company was preparing to launch a novel product used in interventional cardiac surgeries — one that offered improved performance, simplified clinical workflows, and reduced procedure times. The company asked RNA to help it quantify the benefits of the new device in light of direct cost savings, workflow streamlining, and patient safety

Read More
Medical Device Technology

Client Success: Navigating Strategic Investment in Healthcare Technology

THE PROBLEM: A healthcare technology company that sells its FDA 510(k) approved device and supporting dashboarding and analytic tools to hospitals was in the midst of a capital raising effort involving a one-on-one negotiation with an existing strategic partner. The company received from the strategic partner a “low-ball” valuation. The company’s management team and board

Read More

Client Success: Incremental Borrowing Rate Analysis for Publicly Traded, Clinical Stage Biotech

THE PROBLEM:  A publicly traded clinical stage biotech company needed to understand the correct implied discount rate for a lease agreement in accordance with ASC 842 rules. THE SOLUTION: ASC 842 has specific rules relating to leases, including guidance on lease classification (operating versus financial) and how to discount a lessee’s lease payments to arrive

Read More
Medical Device Technology

Client Success: Strategic Extension for Revenue-Stage Medtech Start-up

THE PROBLEM: A medtech start-up with a leading CE-marked product faced a strategic resource allocation decision: invest in next-generation technology in the current low-growth market, or place bets on riskier technologies in the emerging higher growth segment? THE SOLUTION: RNA undertook a comprehensive strategic and commercial operations review, including market segmentation, competitive analysis, assessment of

Read More